NFKB1 and cancer: Furthermore, studies have confirmed that the inhibition of TOP1, such as with topotecan (TPT) or camptothecin (CPT), has antitumour effects (124), driving the activation of the cGAS-NF-κB-PD-L1 pathway in cancer therapy.